DrugPatentWatch Archives

You are currently viewing the 2011 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: JAKAFI

Summary for Tradename: JAKAFI

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: JAKAFI

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: JAKAFI

Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II
Status: Not yet recruiting Condition: Leukemia

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Recruiting Condition: Leukemia

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Status: Completed Condition: Myelofibrosis

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting Condition: Leukemia

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Status: Recruiting Condition: Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis

Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Status: Recruiting Condition: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis

Study of Ruxolitinib in Colorectal Cancer Patients
Status: Recruiting Condition: Metastatic Colorectal Cancer

Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Status: Active, not recruiting Condition: Polycythemia Vera; Essential Thrombocythemia

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Status: Recruiting Condition: Primary Myelofibrosis

Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Status: Recruiting Condition: Breast Cancer, Secondary; Breast Carcinoma; HER-2 Positive Breast Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp
ruxolitinib phosphate
TABLET; ORAL202192Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET; ORAL202192Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET; ORAL202192Nov 16, 2011RXNo7,598,257<disabled>YY<disabled>
Incyte Corp
ruxolitinib phosphate
TABLET; ORAL202192Nov 16, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology